1
|
Bill KLJ, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Lev D, Pollock RE. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. Clin Cancer Res 2016; 22:1150-60. [PMID: 26475335 PMCID: PMC4775372 DOI: 10.1158/1078-0432.ccr-15-1522] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 09/21/2015] [Indexed: 12/23/2022]
Abstract
PURPOSE Dedifferentiated liposarcoma (DDLPS) is an aggressive malignancy that can recur locally or disseminate even after multidisciplinary care. Genetically amplified and expressed MDM2, often referred to as a "hallmark" of DDLPS, mostly sustains a wild-type p53 genotype, substantiating the MDM2:p53 axis as a potential therapeutic target for DDLPS. Here, we report on the preclinical effects of SAR405838, a novel and highly selective MDM2 small-molecule inhibitor, in both in vitro and in vivo DDLPS models. EXPERIMENTAL DESIGN The therapeutic effectiveness of SAR405838 was compared with the known MDM2 antagonists Nutlin-3a and MI-219. The effects of MDM2 inhibition were assessed in both in vitro and in vivo. In vitro and in vivo microarray analyses were performed to assess differentially expressed genes induced by SAR405838, as well as the pathways that these modulated genes enriched. RESULTS SAR405838 effectively stabilized p53 and activated the p53 pathway, resulting in abrogated cellular proliferation, cell-cycle arrest, and apoptosis. Similar results were observed with Nutlin-3a and MI-219; however, significantly higher concentrations were required. In vitro effectiveness of SAR405838 activity was recapitulated in DDLPS xenograft models where significant decreases in tumorigenicity were observed. Microarray analyses revealed genes enriching the p53 signaling pathway as well as genomic stability and DNA damage following SAR405838 treatment. CONCLUSIONS SAR405838 is currently in early-phase clinical trials for a number of malignancies, including sarcoma, and our in vitro and in vivo results support its use as a potential therapeutic strategy for the treatment of DDLPS.
Collapse
Affiliation(s)
- Kate Lynn J Bill
- The Sarcoma Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas. The University of Texas Graduate School of Biomedical Sciences, Houston, Texas. Department of Surgical Oncology, Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio
| | - Jeannine Garnett
- The Sarcoma Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | - XiaoYen Ma
- The Sarcoma Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Chad J Creighton
- The Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
| | - Svetlana Bolshakov
- The Sarcoma Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | | | - Alexander J Lazar
- The Sarcoma Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Bethany C Prudner
- Department of Surgical Oncology, Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio
| | - Lucia Casadei
- Department of Surgical Oncology, Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio
| | - Danielle Braggio
- Department of Surgical Oncology, Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio
| | - Gonzalo Lopez
- Department of Surgical Oncology, Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio
| | - Abbie Zewdu
- Department of Surgical Oncology, Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio
| | - Hemant Bid
- Department of Surgical Oncology, Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio
| | - Dina Lev
- Department of Surgery, The Sheba Medical Center, Tel Aviv, Israel
| | - Raphael E Pollock
- The Sarcoma Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Surgical Oncology, Comprehensive Cancer Center, The Ohio State University (OSU), Columbus, Ohio. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
| |
Collapse
|